| NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients S Malhotra, C Costa, H Eixarch, CW Keller, L Amman, ... Brain 143 (5), 1414-1430, 2020 | 128 | 2020 |
| 2‐AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs M Mecha, A Feliú, I Machín, C Cordero, F Carrillo‐Salinas, L Mestre, ... Glia 66 (7), 1447-1463, 2018 | 47 | 2018 |
| The presence and suppressive activity of myeloid-derived suppressor cells are potentiated after interferon-β treatment in a murine model of multiple sclerosis C Melero-Jerez, M Suardíaz, R Lebrón-Galán, C Marín-Bañasco, ... Neurobiology of disease 127, 13-31, 2019 | 38 | 2019 |
| The proportion of myeloid-derived suppressor cells in the spleen is related to the severity of the clinical course and tissue damage extent in a murine model of multiple sclerosis C Melero-Jerez, A Alonso-Gómez, E Moñivas, R Lebrón-Galán, ... Neurobiology of disease 140, 104869, 2020 | 37 | 2020 |
| Functional heterogeneity of mouse and human brain OPCs: relevance for preclinical studies in Multiple Sclerosis FC Ana Bribián, Eva M. Medina-Rodríguez, Fernando Josa-Prado, Isabel García ... Journal of Clinical Medicine 9 (6), 2020 | 36 | 2020 |
| Tissue-type plasminogen activator exerts EGF-like chemokinetic effects on oligodendrocytes in white matter (re) myelination C Leonetti, R Macrez, M Pruvost, Y Hommet, J Bronsard, A Fournier, ... Molecular neurodegeneration 12, 1-16, 2017 | 22 | 2017 |
| Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis C Camacho-Toledano, I Machín-Díaz, L Calahorra, M Cabañas-Cotillas, ... Journal of neuroinflammation 19 (1), 277, 2022 | 15 | 2022 |
| Central and peripheral myeloid-derived suppressor cell-like cells are closely related to the clinical severity of multiple sclerosis MC Ortega, R Lebrón-Galán, I Machín-Díaz, M Naughton, I Pérez-Molina, ... Acta Neuropathologica 146 (2), 263-282, 2023 | 12 | 2023 |
| Graphene oxide films as a novel tool for the modulation of myeloid-derived suppressor cell activity in the context of multiple sclerosis C Camacho-Toledano, I Machín-Díaz, R Lebrón-Galán, ... Nanoscale 16 (15), 7515-7531, 2024 | 3 | 2024 |
| Myeloid-Derived Suppressor Cells are relevant factors to predict the severity of multiple sclerosis MC Ortega, R Lebrón-Galán, I Machín-Díaz, M Naughton, I Pérez-Molina, ... bioRxiv, 2022.04. 20.488896, 2022 | 1 | 2022 |
| Age-linked heterogeneity among oligodendrocyte precursor cells in the cerebral cortex of mice and human A Bribián, EM Medina-Rodríguez, F Josa-Prado, I García-Álvarez, ... bioRxiv, 799544, 2019 | 1 | 2019 |
| Detection of Monocytic Myeloid-Derived Suppressor Cells in the Human Brain and Blood MC Ortega, V Vila-del Sol, I Machín-Díaz, D Clemente Neural Stem Cells: Methods and Protocols, 89-109, 2025 | | 2025 |
| early-Myeloid-derived suppressor cells: An unexplored potential biomarker of clinical severity and relapse recovery in multiple sclerosis M Cabanas, L Calahorra, I Machin-Diaz, I Alonso-Garcia, R Lebron-Galan, ... MULTIPLE SCLEROSIS JOURNAL 30 (3), 1228-1228, 2024 | | 2024 |
| Circulating Myeloid-Derived Suppressor Cell load and disease severity are associated to an enhanced oligodendroglial production in a murine model of multiple sclerosis MP Serrano-Regal, C Camacho-Toledano, I Alonso-García, MC Ortega, ... bioRxiv, 2024.07. 18.604171, 2024 | | 2024 |
| Circulating monocytic myeloid-derived suppressor cells but not Treg are potential biomarkers of a full relapse recovery in untreated multiple sclerosis patients LC Melero, I Machin-Diaz, I Alonso-Garcia, IP Molina, ... MULTIPLE SCLEROSIS JOURNAL 29, 562-563, 2023 | | 2023 |
| The first full histopathological description of monocytic myeloid-derived suppressor cells in the human brain: relationship to the severity of the clinical course in PPMS patients MC Ortega Munoz, I Machin-Diaz, M Naughton, J Garcia-Arocha, ... MULTIPLE SCLEROSIS JOURNAL 29, 468-469, 2023 | | 2023 |
| CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS AS A POTENTIAL BIOINDICATOR OF THE ENDOGENOUS MYELIN REPAIR CAPACITY IN EXPERIMENTAL MULTIPLE SCLEROSIS MP Serrano-Regal, I Alonso-García, C Camacho-Toledano, I Machin-Diaz, ... IBRO Neuroscience Reports 15, S290-S291, 2023 | | 2023 |
| MYELOID-DERIVED SUPPRESSOR CELL BURDEN IN THE CNS AND BLOOD IS ASSOCIATED WITH DISEASE SEVERITY OF MULTIPLE SCLEROSIS PATIENTS MC Ortega, I Machin-Diaz, M Naughton, I Pérez-Molina, J García-Arocha, ... IBRO Neuroscience Reports 15, S285-S286, 2023 | | 2023 |
| EVOBRUTINIB TREATMENT REDUCES THE DAMAGE TO THE CNS AND INCREASES THE NUMBER OF CLASSICAL DENDRITIC CELLS IN EXPERIMENTAL MULTIPLE SCLEROSIS MP Serrano-Regal, L Calahorra, I Alonso-García, U Boschert, ... IBRO Neuroscience Reports 15, S272-S273, 2023 | | 2023 |
| Evobrutinib Therapeutic Response is Associated with an Increase in the Number and Maturation of Peripheral and Central Classical Dendritic Cells M Serrano-Regal, L Calahorra, I Alonso-Garcia, U Boschert, ... MULTIPLE SCLEROSIS JOURNAL 29, 85-85, 2023 | | 2023 |
